Intravenous indomethacin and changes of renal function in premature infants with patent ductus arteriosus.
Selected parameters of renal function were studied in premature infants with a significant patent ductus arteriosus who were treated with intravenous indomethacin according to a specific protocol. Urine volume, glomerular filtration rate, urine sodium, and the fractional excretion of sodium were analyzed in 17; osmolar, sodium, and free water clearances in 8; and indomethacin pharmacokinetics in 7 premature infants. All renal function parameters analyzed decreased during indomethacin therapy: urine volume and glomerular filtration rate returned to normal, while urine sodium, fractional excretion of sodium, and the osmolar, sodium, and free water clearances remained low 24 hours after cessation of therapy. The water retention, shown by the reduced free water clearance, had no apparent deleterious effects, probably because of the infants' low fluid intake. Indomethacin pharmacokinetic parameters (clearance, area under the curve) may account in part for the variability of the fractional excretion of sodium, glomerular filtration, and urine flow rate.
D004374:Ductus Arteriosus, Patent / Q000188:drug therapy* / Q000503:physiopathology; D005919:Glomerular Filtration Rate; D006801:Humans; D007213:Indomethacin / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D007231:Infant, Newborn; D007234:Infant, Premature; D007275:Injections, Intravenous; D007677:Kidney Function Tests; D007700:Kinetics; D011446:Prospective Studies; D012964:Sodium / Q000652:urine*
D012964:Sodium; D007213:Indomethacin